Updated: Sep 29, 2022
BUILDING BLOCKS OF RESPIRATORY SYSTEM
According to American Lung Association, Your respiratory system (or pulmonary system) is responsible for breathing. This system enables you to inhale oxygen into your blood and exhale carbon dioxide.
Your body needs the oxygen to survive, and carbon dioxide must be removed to avoid the build-up of acid in your body.
You normally breathe without thinking about it, but your brain is carefully coordinating this activity. Your brain sends signals down your spinal cord to the Phrenic nerves which start sending signals to cervical spinal levels to contract the diaphragm
(The diaphragm is located just under the lungs. It is the major muscle of respiration. It is a large, dome-shaped muscle that contracts rhythmically and continually. Upon inhalation, the diaphragm contracts and flattens and the chest cavity enlarges).
CURRENT STATE OF TUBERCULOSIS TREATMENT
Tuberculosis (TB) is still a major global health problem even with the slightly decreasing incidence in recent years.Anti-TB therapy relies on combined effect of bactericidal and anti-inflammatory drugs that can effectively reduce drug-resistance.
The crucial point of TB treatment regimen is security and practicability. Ideally, a novel drug should be able to interact with other drugs freely, and without competing with or causing resistance of current drugs, especially multidrug-resistance.
The nitroimidazooxazine PA-824 ( Pretomanid ) represents a new class of anti-tubercular drugs. PA-824 is one of the novel bicyclic nitroimidazole drugs for TB treatment that has already been in phase II clinical trials, and the other one is OPC-67683.
PA-824 has potent activity against Mycobacterium tuberculosis (M.tb) in vitro (external artificial environment), and does not demonstrate cross-resistance to a variety of commonly used anti-TB drugs.
Although antibacterial activity of PA-824 to M.tb and multidrug resistance were evaluated, the exact mechanism is not well known.
PROPOSED RESULTS WITH ADENOSINE THERAPY ON TUBERCULOSIS
For the Adenosine therapy, the study proposed an immune-modulatory compound named 3'-Deoxyadenosine derived from a rare species of C.Sinensis. Effects of this compound later are seen in the positive light when used along with PA-824 also marketed as Pretomanid.
As we see here the Colony- Forming Units/Counts has shown an immense decline if dosed with 10 mg/kg Pretomanid ( Body weight Index ) and 200 mg/kg C.Sinensis Extract ( Body weight Index ) water based extract in a span of just 8 weeks.
In an ideal setting, this dosing can work much more effectively than
PA-824 and C.Sinensis Extract alone.
Although Pretomanid Tablets, Bedaquiline and Linezolid Combination Regimen has shown a fair amount of side-effects including Peripheral Neuropathy being one of the top reported one during the clinical studies.
Showcasing how just PA-824 (in a controlled dosing) along with Cordyceps Sinensis can offer a superior improvement for the Tuberculosis treatment regime.
CURRENT STATE OF ASTHMA TREATMENT
Asthma is a chronic disease of the upper respiratory tract that occurs as a result of bronchial hyper-inflammation and airway hyper-responsiveness.
A high percentage of patients suffer from uncontrolled asthma that is attributed to increased secretion of IgE, resulting from the recruitment of inflammatory cells such as Th2 cells and eosinophils to the airway tissue and the bronchoalveolar fluid.
These patients are at high risk of asthma-associated mortality and hospitalization and experience significant impairments in the quality of life. The disease may have varying degrees of impact on the physical, psychological, and social wellbeing of people. Subjects with asthma are less likely to report excellent health, compared with people without the condition, whereas asthma ranks fourth, after cancer and kidney disease in the list of diseases that force people to request time off work,
school, or study .
Moreover, patients with asthma often experience comorbidities, such as rhinitis, obesity, and cardiovascular disease. Thus, the international guidelines for asthma therapies aim to achieve and maintain long-term con- trol of the disease, in order to improve the quality of life of the patient by minimizing the symptoms and improving physical, psychological, and social function. Indeed, improvements in health-related QOL (HR-QOL) may be more reflective of treatment success, compared with physiological endpoints such as spirometric measures of lung function.
PROPOSED RESULTS WITH ADENOSINE THERAPY ON ASTHMA
Herbal medicines combined with routine pharmacotherapies were used in some previous studies in treatment of asthma. The integrated approach improved outcomes greater than pharmacotherapies alone.
There were studies using herbal decoctions combined with routine pharmacotherapies that showed improving FEV1 (Flowed Expiratory Volume) & PEFR ( Peak Expiratory Flow Rate).
The Adenosine Therapy improved the quality of life of the patients by reducing asthma-related symptoms and asthma onset frequency and severity, while it significantly attenuated asthma-induced inflammation at the 3-month intervention period, as demonstrated by decreased expression of inflammatory biomarkers.
PROPOSED RESULTS WITH ADENOSINE THERAPY ON LUNG CANCER
During this particular therapy, The C.Sinensis Water extract was used along with Wild Panax Ginseng water extract and T.Kirilowii water extract in a form of Pharma-acupuncture.
C. sinensis has been reported to have pro-apoptotic effects on human lung adenocarci- noma A549 cells, to prolong the survival of hepatocellular cancer patients and to act as an adjuvant in cancer therapy.
T. kirilowii has been reported to have an antitumor effect through experiments using HeLa cells, B16-F10 melanoma cells and A549 lung cancer cells.
Thus, W.Ginseng , C.Sinensis , T.Kirilowii are perceived with their efficacy in treatment of lung cancer and therefore used in this case. As a result, the ECOG scale was improved from 2 to 1, and the size of the tumor, which increased from 48 to 54 mm in the 2 months without any treatment, Showed decline from 54 to 11 mm within 6-7 months of Adenosine Therapy.
PROPOSED RESULTS WITH ADENOSINE THERAPY ON
The promising results and past study cases contains a substantial amount of positive data that supports the use of Adenosine therapy in the diseases mentioned above. For more details please reach out to us through our contact us form.